Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HER2-low expression in patients with advanced or metastatic solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.08.005Source: DataRank Database

HER2-low expression in patients with advanced or metastatic solid tumors is a research paper published in Annals of Oncology (2023). On theSindex it has a DataRank of 0. It has been cited 72 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access72 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 8.54)OA: bronzeTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (25)

Cara Haymaker ORCID,Gabriela Raso,Serena Masciari,Lei Wang ORCID,Heather Lin ORCID

Live enrichment

PubMed:37619847 PMC:PMC11670753 OpenAlex:https://openalex.org/W4386057282

National Cancer Institute

Grant: P30 CA016672

Center for Clinical and Translational Science, University of Illinois at Chicago

Grant: 5UL1TR003167-03

NCATS NIH HHS

Grant: UL1 TR003167

National Institutes of Health

FWCI

8.54

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.annalsofoncology.org/article/S0923753423008037/pdf

publisherhttp://www.annalsofoncology.org/article/S0923753423008037/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0923753423008037?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0923753423008037?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.annonc.2023.08.005

Fields of Study

HER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesCancer Cells and Metastasis

MeSH Terms

Breast NeoplasmsFemaleHumansImmunohistochemistryBiomarkers, TumorNeoplasms, Second PrimaryIn Situ HybridizationReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesGenomics

Keywords

MedicineImmunohistochemistryMetastatic breast cancerBreast cancerConcordanceCancerTrastuzumabHER2/neuPathologyOncologyGene duplicationInternal medicinePrimary tumorMetastasisBiologyGeneTargeted TherapyHer2 AmplificationHer2 ExpressionErbb2 AmplificationHer2-low

Sustainable Development Goals

SDG 0: Good health and well-being

HER2-low expression in patients with advanced or metastatic solid tumors

FAIR Checklist

Authors (25)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)